ZW 220
Alternative Names: ZW-220Latest Information Update: 14 Jan 2025
Price :
$50 *
At a glance
- Originator Zymeworks
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 08 Jan 2025 Zymeworks plans a first in human phase I clinical trial for Solid tumors in 2025
- 04 Nov 2024 Pharmacodynamics and adverse events data from the preclinical studies in Cancer released by Zymeworks
- 23 Oct 2024 Pharmacodynamics, pharmacokinetics and adverse events data from the preclinical studies in Cancer presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)